Nektar Therapeutics (NKTR) Earnings Call Transcript & Summary
March 12, 2026
Earnings Call Speaker Segments
Vivian Wu
executiveThanks, Crystal, and good afternoon to all of you. We appreciate you being with us today. Speaking on today's call will be Howard W. Robin, our President and Chief Executive Officer; Dr. Jonathan Zalevsky, our Chief Research and Development Officer; and Sandra A. Gardiner, our Chief Financial Officer. Dr. Mary Tagliaferri, our Chief Medical Officer, will also be around for the Q&A. These statements carry risks and uncertainties that are hard to foresee and many of which lie beyond our control. The results we actually achieve could differ materially from what these statements suggest. Key risks and uncertainties appear in our most recent Form 10-Q, which you can find at sec.gov; we assume no duty to revise any of these forward-looking statements, whether because of fresh information, later developments, or any other reason. A webcast of this call will be posted on the IR page of Nektar Therapeutics' website at ir.nektar.com. So with that, I'd like to turn things over to our President and CEO, Howard W. Robin. Howard?
Howard W. Robin
executiveThank you, Vivian, and good afternoon, everyone. For Nektar Therapeutics, 2025 stood out as a transformative period, and we are carrying that momentum forward with meaningful advances in 2026. Back in 2023, we shared our intention to concentrate on progressing our immunology and inflammation pipeline programs, all built around the biology of T regulatory cells. That October, we launched the first phase 2 trial of our novel Treg biologic Respag Aldesleukin in people living with moderate to severe atopic dermatitis. Early in 2024, a second phase 2 study got underway in alopecia areata. Then just last year, we initiated a third phase 2 study in type 1 diabetes together with our collaborator TrialNet, which is providing the funding and sponsorship for that trial. During 2025, the hard work of our team over multiple years paid off when we reported the first positive findings from the two phase 2b studies of Rezpeg in atopic dermatitis and alopecia areata. Those results confirmed that our novel regulatory T cell mechanism could deliver clinically meaningful benefits in two dermatological and inflammatory disease settings. Just last month, we also shared long-term monthly and quarterly dosing data from the 36-week maintenance part of Resolve AD in atopic dermatitis. These data pointed to strong durability of effect that is highly competitive with what other biologics have shown and demonstrates what our novel Treg mechanism can accomplish. Giving ResVeg monthly or quarterly during the maintenance phase produced a deepening of response, with gains in EASI-75, EASI-90, and up to a fivefold rise in EASI-100 scores. Both atopic dermatitis and alopecia areata are inflammatory skin diseases that affect a large number of patients around the world. In the U.S. alone, more than 15 million people have moderate to severe atopic dermatitis. It is currently estimated that only 10% to 15% of patients receive biologic therapy for this chronic skin condition. With the rapid uptake of biologics, the atopic dermatitis market is projected to reach $35 billion by the mid-2030s. Dupixent and IL-13s are the most widely used treatments today for these patients, but around 50% of patients do not respond or lose treatment benefit over time with IL-13 based approaches. That leaves a substantial opening for a novel immune modulating mechanism such as Rezbeg to enter the treatment landscape. The competitive field for late-stage novel MOAs advancing toward a BLA filing has also narrowed recently. We see this placing Respect in a leading position as a novel MOA that could provide differentiated efficacy and safety, a more convenient dosing schedule, and the possibility of complete disease clearance for patients over time. In alopecia areata, there is still an unmet need for a safe and effective biologic with improved efficacy and dosing characteristics. Approved JAK inhibitors can regrow hair for certain patients, but they come with several disadvantages, and over half of doctors and patients are reluctant to use them because of safety concerns and the monitoring burden involved. Notably, the JAK class does not last well—after stopping treatment, almost every patient sheds the regrown hair. Having seen the 36-week results from RESOLVE AA, which show a clinical efficacy profile comparable to low-dose JAK inhibitors in alopecia, we are eager to see the 52-week data from that trial in April. For those who move into the blinded 16-week treatment extension, we will assess whether ResMed can drive deeper SALT reductions, including zoo SALT 20 responses. Rizpeg’s distinct clinical profile plus a safety database covering more than 1,000 treated patients to date, equal to 381 patient-years of exposure, gives us a remarkably strong foundation for moving ResMed into phase 3 studies. In June, the first patient will be randomized in the phase 3 atopic dermatitis trials; we have now reached agreement with the FDA on our phase 3 dose, the 24-week induction treatment period, and other key phase 3 design components. Jay Z will go over that shortly. We anticipate first phase 3 data in mid-2028 and remain on track to submit a BLA in 2029. We closed 2025 with $245.8 million in cash and investments and no debt on the balance sheet. Since the end of the year, we have also brought in roughly $476 million in additional net cash through a public offering and by using a portion of our ATM. Our balance sheet is now strong enough to let us advance rapidly into phase 3. I’ll now hand the call to Jay Z, who will provide more detail on RespEG and our other immunology programs. Jay Z?
Jonathan Zalevsky
executiveThanks, Howard. First, I want to walk through more specifics regarding the substantial headway we've achieved with Respag, which Howard mentioned a short while ago. Respag is an extremely distinctive Treg biologic that leverages a key immune pathway. Engineered as a highly selective agonist targeting regulatory T cells, it aims to tackle the fundamental immune equilibrium across several inflammatory pathways. Looking back across the last twelve months, the data from our phase 2 studies have shown Respag to be truly distinct — it works through a novel MOA, it's a late-stage biologic candidate with a strong efficacy profile, and on top of that it offers the option of extended dosing intervals. Those phase 2 results sit on top of what we saw in the earlier phase 1 trial for Respact, where patients showed the potential for disease control or remission lasting 36 weeks after coming off the drug. As things stand today, Respag is ready to move into phase 3. On top of that, we have one of the biggest safety databases among agents in mid to late-stage development for atopic dermatitis — it now covers more than 1,000 patients, which works out to roughly 381 patient-years of exposure. When it comes to atopic dermatitis, the 16-week induction results we shared last June showed ResMed works quickly on important efficacy measures—after just one or two doses, it pulled ahead of placebo on EASI-75, EASI-90, and itch relief. Also worth highlighting: those induction findings made Respag the first new MOA proven to deliver substantial itch reduction alongside skin clearance, all without topical corticosteroids being required. Itch relief, as we know, plays a big part in driving better sleep scores and improved quality of life for atopic dermatitis patients, and in our trial that carried through to statistical significance on those patient-reported outcomes too. When patients received the 24 mcg/kg high dose on a biweekly schedule during induction, the efficacy numbers we observed for EASI-75 and EASI-90 were similar across those with moderate and those with severe disease who took part in the trial. Stratification of the study relied on baseline vIGA scores of four and three, and results proved comparable between those two groups. This characteristic stands out as an important point of differentiation relative to what Dupixent has demonstrated. Additionally, Respag has generated encouraging positive findings when used to treat atopic dermatitis patients who reported comorbid asthma. That dataset, covering the ACQ-5 endpoints from Bresolve AD, was presented by us at ACAI last year. When you look beyond Dupixent, there isn't another treatment that's already approved or still being studied that has demonstrated it can help with atopic dermatitis and asthma occurring together. In the induction phase, Respag produced improvements in ACQ-5 scores at 16 that were both statistically significant and clinically meaningful compared with placebo, and among patients whose asthma was uncontrolled at the start, 75% saw improvement in those scores. Roughly a quarter of people with atopic dermatitis also struggle with asthma, and Respag stands alone as the only new mechanism of action showing gains on this measure. Then last month we shared the 36-week maintenance results, which revealed two more important qualities of Respag that set it apart from both approved therapies and ones still in development. To start with, we observed meaningful durability of efficacy, and we also observed that responses got deeper as treatment went on, out to 52 weeks, with gains across the EASI-75, EASI-90, itch, and vIGA endpoints. Of note, we observed as much as a fivefold gain at EASI-100, as Howard said before, which highlights how Respag could deliver full disease clearance for patients when treatment continues over a longer period, and sets a fresh standard in atopic dermatitis; and second, we confirmed that extended monthly and quarterly dosing may serve as a long-term regimen with Respag once responses have been induced. To reiterate what I mentioned earlier, Respag has accumulated over 1,000 patients who have received doses, amounting to approximately 381 patient-years of exposure, and this supports a favorable, well-established long-term safety profile. Based on the data we shared, our safety profile stands apart, showing no increased likelihood of systemic adverse events such as conjunctivitis, infection, or malignancy. The RESOLVE AD findings informed how we structured our phase 3 program, and this June we will kick off the first pivotal study. Following our end of phase 2 meeting, we have now reached agreement on the strategy for a phase 3 program that will evaluate a single 24 mcg/kg dose given twice monthly during the 24-week induction period. Following their EASI-75 or vIGA response, participants will undergo another randomization into either monthly or quarterly dosing schedules, continuing through week 52. The phase 3 structure is going to mirror what was used in registration trials for other biologic therapies. As has been done in other phase 3 studies, we intend to employ a primary endpoint tied to vIGA that U.S. registration demands, along with a secondary EASI-75 endpoint to back EU approval. Both biologic-naive individuals and those with prior treatment experience will be evaluated in our phase 3 program. Turning to areas outside atopic dermatitis, in December we generated proof-of-concept results from RESOLVE AA involving Respag for severe to very severe alopecia areata. We were delighted that this data was selected as a late-breaking presentation for the AAD meeting happening this March. Among all alopecia areata datasets, this was the sole one chosen for the late-breaking session. As we shared in December, the RESOLVE AA trial showed Rezpeg delivering an efficacy response that matched what we set out in our target product profile: efficacy comparable to low-dose JAK inhibition by week 36 when dosed once every two weeks, plus a safety profile that stays more appealing and favorable. In our view, these results set RespEx up as a possible first-in-class biologic for alopecia. Howard mentioned earlier that RESOLVE AA also featured a blinded 16-week extension phase, open to patients who completed week 36 without having yet reached a SALT 20 score. Our intention is to share results from the treatment extension during April. So, starting on April 1, we'll enter a quiet period, which will last until we unblind and disclose those treatment extension findings. Just to note, when it comes to systemic options cleared by the FDA for alopecia areata, JAK inhibitors are the sole ones available; however, they carry several black box warnings along with lab monitoring obligations. On top of that, nearly all patients experience their hair shedding again after they discontinue therapy. Since alopecia areata patients have so few treatment options available, we believe there's a unique opportunity for a novel Treg immune-modulating approach like Respec—one that offers more convenient dosing than a daily pill and potentially a better safety profile. Following the data from our 16-week treatment extension, we expect to hold our end-of-phase-2 meeting with the FDA for alopecia areata sometime in the second quarter of this year. After that meeting takes place, we plan to provide more specifics about how we'll advance into phase 3. Before I move on to discuss our earlier antibody program, I'd like to mention the ongoing phase 2 trial we're conducting with Respag in type 1 diabetes. TrialNet is sponsoring and paying for this study, which is looking at Respag in patients who have just been diagnosed with stage 3 type 1 diabetes. Under the protocol, participants get assigned randomly at a 2:1 ratio against placebo, and they take Respag once every two weeks across a six-month period. Three cohorts make up the study; it begins with adults between 18 and 45 years old, then moves to patients down to age 12, and after that to those as young as 8. Working alongside TrialNet is something we're thrilled about. This group consists of type 1 diabetes experts throughout the U.S.
Jonathan Zalevsky
executiveWe were the ones who conducted the initial trials for Tisdale, which is also called teplizumab, in type 1 diabetes. There is a deep dedication on their part to discovering and assessing novel treatments that might benefit people facing this terrible condition. We believe and anticipate seeing preliminary results from the sponsored phase 2 study at some point during 2027. A key principle guiding our efforts is that by developing a first-in-class approach aimed at Tregs, such as RESTPAC, we have verified something we as immunologists have long sensed — that Tregs play a vital role in numerous diseases and might be targeted therapeutically to treat illness. Drawing on low-dose IL-2 and Treg biology, whether through genetic means or clinical assessment, we recognize there are many more indications beyond those we are currently investigating in our ongoing phase 2 trials that represent possible chances for Respect. These encompass therapeutic fields like our skin, and autoimmune conditions, THC such as food allergies, or asthma where a signal has already been observed, and chronic rhinosinusitis. It also covers skin conditions like dermatomyositis, and possibly immune-related diseases such as Sjogren's syndrome. As we move Respag into phase 3, we anticipate the chance to produce further proof-of-concept information in additional indications, which might broaden the eventual label for RespEx. Shifting to our earlier pipeline candidates. NKTR-0165 and NKTR-0166, our TNFR2 agonist and bispecific initiatives. We anticipate sharing preclinical findings from this initiative at a scientific meeting in 2026. This molecule demonstrates extremely high selectivity for signaling via TNFR2 on Tregs to boost and refine their capacity to modulate the immune system, which we think might have an effect on multiple sclerosis, ulcerative colitis, vitiligo, and other I&I indications. During the first quarter, we disclosed an academic research partnership for NKTR-0165 with Dr. Steven Hauser at UCSF to investigate the possible function of TNFR2 agonism in lessening neurodegeneration, encouraging neuroprotection, and cellular repair. The research funded by UCSF will examine Nektar-0165 in patient-derived B-cell models of multiple sclerosis. We look forward to collaborating with Dr. Hauser to guide upcoming development efforts for this crucial molecule. Building on our insights from creating NKTR-0165, we have crafted a bispecific molecule named NKTR-0166; this bivalent antibody includes a TNFR2 agonist epitope along with an antagonist epitope that was previously validated in treating rheumatology conditions. As a dual agonist/antagonist of established pathways, NKTR-0166 could potentially alter disease pathogenesis across several autoimmune disorders. And we are preparing for IND submission for one or both programs in 2027. With that said, I will now hand things over to Sandy to discuss the financials. Thank you, Jay Z, and good afternoon to all of you.
Sandra A. Gardiner
executiveDuring this call, I'll go over our results for the quarter and for the entire 2025 fiscal year, and I'll also discuss the preliminary financial outlook we're providing for 2026. As 2025 came to a close, we held $245.8 million in cash and investments, and our balance sheet carried no debt; during February, we wrapped up an underwritten public offering totaling $460 million, which yielded roughly $432 million in net cash proceeds for the company; additionally, during 2026 we have drawn down approximately $44 million in net proceeds so far from our existing $110 million ATM facility. With this solid balance sheet in place, we can put capital to work in our pipeline and move our phase 3 program in ResPay forward. Let me now give you a brief rundown of our 2025 financial results. Revenue came in at $21.8 million for the fourth quarter and $55.2 million across the full year 2025. R&D expenses totaled $29.7 million in the fourth quarter and $117.3 million for the entire year. G&A expenses amounted to $11.2 million for the fourth quarter and $68.7 million for the full year. Non-cash interest expense was $9.8 million in the fourth quarter and $26.2 million for the full year. Net loss for the fourth quarter reached $36.1 million, or $1.78 basic and diluted net loss per share. Across the full year of 2025, net loss came to $164.1 million, or $9.73 basic and diluted net loss per share; on this call we're offering highly preliminary guidance for 2026. These guidance ranges are broad because planning and budgeting work for the Respag phase 3 program is still being finalized. Last year we started putting money into startup activities for that program, including manufacturing of drug supply and placebo; and as Howard mentioned previously, we intend to randomize our first patient during June. We anticipate having a revised 2026 budget by then and will adjust our financial guidance if needed. Regarding our 2026 P&L outlook, non-cash royalty revenue for the full year 2026 should land somewhere between $40 million and $45 million. According to our present forecast, full-year R&D expense might fall in a range of $200 million to $250 million, which includes roughly $5 million to $10 million in non-cash depreciation and stock-based compensation expense; we anticipate G&A expense will come down in 2026 relative to 2025, landing in a range of $60 million to $65 million. That figure includes about $5 million of non-cash depreciation and stock-based compensation expense. Full-year non-cash interest expense should be somewhere between $30 million and $35 million. In addition, we don't anticipate any material gain or loss on our equity method investment during 2026. Finally, we expect to finish 2026 with roughly $400 million to $460 million in cash and investments. With that, let's open the call for questions. Operator?
Yasmeen Rahimi
analystAfternoon, everyone, and thanks a lot for the wonderful updates. Perhaps a fast two-part question. First, congratulations on the RESOLVE AA study presentation at the AAD — Jay Z, I'd like to grasp what kind of fresh data we might get to see. Was it mostly a chance to put it on display? Second, could you help us set expectations for this blinded 16-week treatment extension period? For ResPEG to be viewed as highly competitive, what does it need to demonstrate regarding mean SALT reduction and SALT 20 as well? Thanks — I'll rejoin the queue.
Jonathan Zalevsky
executiveThank you, Yasmeen. Regarding what we'll present down the road and in upcoming data disclosures, bear in mind the trial's design: a 36-week treatment period. Yet patients who had started regrowing hair without hitting a SALT 20 were allowed to move into an extra 16-week extension — a portion of the study that was also blinded — where dosing could continue through week 52. When we shared the data in December, we had already noted that three patients had by then entered that period as of that December data cut at the time we presented last year's results, and those three had already achieved the SALT 20 beyond week 36. Those patients weren't even counted in the week 36 numerator, since their response came later. So, when you ask about the tone of the presentation we'll give, once our quiet period starts in April and after the top-line results are out, we'll share the added treatment effect with Respag and how many more patients might potentially convert to SALT 20 responses, along with further deepening of their SALT reductions across that extra 16-week treatment period. I think you may be starting to glimpse a paradigm similar to what we saw in atopic dermatitis when dosing duration was extended to week two in maintenance. Those given raspeg kept building additional efficacy, and we believe that same potential could exist in alopecia areata, given we've already seen three patients respond that way. So we'll share the totality of that patient population. Every patient who entered that extension period will have completed week 52, and that's what the results will look like. As for what we'd want to see to call it competitive, BEST PAC has already shown a profile quite distinct from a JAK inhibitor. You look at every benefit that comes with hair regrowth, yet that has to be weighed against the drawbacks — and as both Howard and I said during our presentation, the safety problems and risks are quite substantial, which could make chronic use of a JAK inhibitor extremely difficult. In particular, this drug class is hard for dermatologists to prescribe because of the lab monitoring required, plus the extra burden and risk borne by patients. And once someone must discontinue a JAK inhibitor for whatever reason, essentially all patients lose every strand they may have regrown while receiving that JAK inhibitor. So what we want to see is an efficacy profile that gets to low-dose ILUMENTE. I believe our chances of reaching that level are very good. Beyond that, we want to provide everything else Respect has already demonstrated: a safety profile that is fully differentiated, a dosing schedule far more convenient than a once-a-day pill, and truly the chance to offer a significantly better biologic that can be given chronically for this chronic condition. Thanks for asking that, Yasmeen. Thank you.
Julian Harrison
analystHello, and thanks for fielding the questions — congratulations on the progress. About the phase 3 program in atopic dermatitis that should kick off next quarter, do you anticipate the ACQ-5 data will find its way into a possible label from those trials? If that happens, I'm curious how much of a commercial boost you'd expect that to provide compared with dual labeling, in both atopic derm and asthma. And then, apologies if this was already covered. I'd also like to know what share of bio-experienced patients you intend to enroll in your upcoming atopic dermatitis trial. Is there a set target for that?
Howard W. Robin
executiveSure. Mary, would you like to take that one?
Mary Tagliaferri
executiveAlright, hello. So the ACQ-5 is being included in the phase 3 program, and at baseline and throughout induction we'll evaluate it, and then through maintenance we will also assess the ACQ-5; and for the ACQ-5 we intend to power, and multiplicity control will be applied. And we will, you know, do everything possible to get that into the label, and that certainly forms one part of our plan. Regarding bio-experienced patients, in our phase 3 program we expect about 25% of patients to be bio-experienced, while 75% of patients will be naive to biologic/JAK inhibitor.
Julian Harrison
analystThat's really useful. Thanks. Hello, my name is Sean, and I'm on the line on Jay's behalf. I appreciate you taking my question, and congratulations on the progress you've made. Turning to the AD portion, I'd like to know, for the phase 3 study as well as any eventual commercial release, what device or formulation is being used for RedfinQ at this point? Also, I'm curious whether there's any protocol direction or an ISR mitigation strategy being implemented for your phase 3, or whether you consider that to be needed. Thanks.
Jonathan Zalevsky
executiveYes. Hello, absolutely. I can address the formulation portion, and after that I'll hand things over to you, Mary. Respag is an agent given at a very low volume, so most patients get 1 milliliter, with 2 mL being the maximum, based on how much they weigh. Our intention is to conduct phase 3 the same way we conducted phase 2, in which the drug came as a vial, and then, at the study site, staff at the study centers draw it up and give it to the patient. For the commercial launch, though, our plan is to bring Respag to market in an auto-injector, paired with an auto-injector device. To do that, we'll move to something known as weight-banded dosing, meaning weight-based dosing won't be necessary since patients get doses matched to their body weight. We recognize that this brings plenty of opportunities as well as advantages. It will be a highly straightforward product patients give themselves, quite similar to every biologic that comes in single-use pen devices. As for some of the ways we'll conduct phase 3, I'll pass that along to Mary.
Mary Tagliaferri
executiveAlright, hi. So to start off, I believe it makes sense for us to go through the ISR cases observed throughout our program. Of those, 99% were mild to moderate in severity — the vast majority being mild — while just 1% were severe. Also, we're seeing an extremely low rate of discontinuation because of ISRs. That's because these reactions don't resemble what we're seeing with PULS. When it launched, pain isn't something we commonly observe, and pruritus isn't commonly observed either. Most patients — 96% — simply experience erythema, meaning redness. And in the same way, patients aren't getting ISRs with every single injection they receive; actually, what we observe is that most patients really have only 2 or fewer over the whole treatment period. As for how these get managed, patients apply cold compresses using ice. If it's necessary, they're also able to use a topical corticosteroid. However, given that most patients don't experience pruritus, for the most part, there's no need for patients to use a topical corticosteroid. We, you know, had Dr. Jonathan Silverbirds join us during our last presentation of the maintenance data. You know, he definitely emphasized that this trade-off is an easy decision for patients; these patients, you know, are dealing with severe itch, and since Rezpeg provides that very rapid itch relief along with resolution of atopic dermatitis, while the trade-off is an erythematous ISR, that, you know, on the whole, the risk-benefit strongly favors ResTech as a treatment for atopic dermatitis.
Mary Tagliaferri
executiveQ (Sean (for Jay Olson, Oppenheimer)): Excellent. Many thanks.
Roger Song
analystExcellent. Congratulations on the advancement, and I appreciate you fielding my question. What I'd like to ask about, I believe, concerns the most recent data cutoff regarding alopecia areata. You've got 3 patients who hit SALT 20, plus an additional 7 patients who hit SALT 30. I'm just wondering, what dosing was used for those 3 and those 7 patients? And then, if they're deepening the response, since you're moving toward high-dose ILUMEN, based on your market research and your adviser, would this efficacy at high-dose ILUMYA alter the potential clinical adoption relative to the low dose? Thank you.
Mary Tagliaferri
executiveYes. Hello, Roger. Yes. So, thank you, Roger.
Jonathan Zalevsky
executiveRaj, thanks for asking. Let me just emphasize once more that this trial remains blinded, correct? Therefore, once we reveal the findings shortly, during April, we'll lift the blind and show every result belonging to each participant who reached the extension phase. That means we'll have a fresh update arriving extremely soon. Now regarding the TPP, a key point is that this therapy is a biologic, offering an entirely distinct profile. From the start, our aim was hitting the TPP associated with low-dose JAK inhibitor Lumant. Based on the data in hand, we feel we've already achieved it. In our view, 52 weeks represents the proper extension length. Take the phase 3 we're planning: we know treatment would extend beyond 36 weeks. We also recognize that extra treatment time creates a chance to perhaps draw out even greater efficacy. There's essentially a blank-canvas sort of opening here, since when a biologic first enters an autoimmune indication, it may dramatically reshape how physicians write prescriptions. A lot of doctors feel far more at ease prescribing a safer biologic rather than something harder to manage and possibly trickier, such as a JAK inhibitor. So this is something we're tremendously enthusiastic about; plus it's a data update we genuinely can't wait to see. And it's a TPP we believe may become a truly major opportunity for Respag down the road.
Mary Tagliaferri
executiveUnderstood. Many thanks.
Mayank Mamtani
analystRight. Hello, everyone. Appreciate you fielding our questions, and congratulations on the advances. So here comes another alopecia question. Apologies in case I overlooked this. What additional data, compared with the December update, would you be presenting at the conference? And could you speak to any strategy for putting out the off-therapy data regarding the responders you had? I recall that efficacy responses were still rising within the 16-week extension, so I was unsure when you would examine the off-therapy data. And then one broader question for Howard, if that is alright. The EASI-100 responder rate — how significant do you consider it as a point of differentiation? I realize not many agents reach that level. I am also asking with the original framing in mind of a big, expanding ATD market, which might see several new players around the time you launch in 2029. I get that the short-term launch picture has definitely gotten narrower, but we are thinking further out.
Howard W. Robin
executiveFine, I will take the final portion of the question first, and then hand it to Jay Z and Mary. In my view, EASI-100 has not been examined all that carefully, and it has not been reported all that often, since extremely few people reach the levels we have managed to reach. So when you look at the maintenance data, where we got, you know, roughly 30% EASI-100 scores, again, I believe that matters a great deal, and it results in, essentially, it results in what amounts to complete clearance of the disease in these patients as time goes on; and it has not gotten much discussion, and everyone talks about 75 and 90. The reason is that reaching EASI-100 is truly hard, and we have achieved it. So I think that speaks volumes about what the Treg mechanism can do generally. I will hand the remainder of the question to Jay Z and Mary.
Jonathan Zalevsky
executiveOkay, thank you, Howard. And Mayank, you packed a lot into a single query — it had 12 parts. So I want to be certain I address each one. Regarding the AAD presentation, that's only a couple of weeks away. You'll be able to view all the data that gets shown, and a physician will be delivering it at the medical conference. As for the remaining portion of the study, there's a catalyst coming in the later part of this year — the 24-week off-drug evaluation period from the alopecia areata trial. However, that won't be information we discuss at AAD or during the April data presentation, since that one is focused solely on end treatment at week 52. During the latter half of this year, specifically in Q4, we'll share the findings from that 24-week off-drug period. So those are simply upcoming catalysts to anticipate for Respag in alopecia areata. I appreciate your question.
Mayank Mamtani
analystThank you.
Jonathan Zalevsky
executiveThank you.
Samantha Semenkow
analystWhat about the C-peptide preservation data? And if I could fit in one more, just thinking more broadly, when you consider moving ResPEG into other indications — you brought up several during your prepared remarks, Jay Z — how do you weigh which ones would be the earliest candidates to potentially go into the clinic? Thanks so much.
Jonathan Zalevsky
executiveOkay. Thank you. Thank you, Sam. So in type 1 diabetes, it was quite fascinating, since TrialNet was in fact searching for an approach targeting regulatory T cells. And it was quite thrilling because there was considerable shared motivation to move that ahead. Also, it proved a highly competitive process collaborating with them, given the many options available to them. We felt tremendous excitement that they chose Respag to conduct the study. Now, one of the fundamental scientific themes is that there exists a widely recognized theory regarding regulatory T cells' function in this disease — namely how thymic antigens become, you know, harmful by driving autoreactivity against the islet cells, and afterward a loss of Treg control, you know, truly, truly worsened that. So the aim was to raise Tregs in these patients so as to slow the disease's progression and, ideally, you know, defeat it entirely. And so the initial stage in pursuing this long mission is this therapeutic intervention study. This trial is in fact conducted much like the earliest teplizumab studies were conducted. The major distinction is that we administer a six-month treatment, rather than merely a brief, you know, burst — only a few weeks — which is how tefluncimab is dosed. Then the objective is, naturally, to genuinely reduce the pace of decline. There will be a chance for early data next year, and it is somewhat premature to state the full extent of what that would be, Sam; nonetheless, yes, a mixed-meal tolerance test, right, using C-peptides is clearly among the study's key endpoints, together with HbA1c levels and also insulin usage; and so those are the key activities being monitored in the patients. And it is a well-designed study with likely the most highly qualified team of people to perform that kind of study within the TrialNet consortium; and as for the other indications, it remains something we are deciding on — which indications and which ways to go. But I believe we have witnessed so many examples of data from our own program that would truly make certain indications quite attractive. I think it is quite clear that this mechanism in both skin diseases and in diseases having a TH2 drive holds quite a lot of potential. Observing the outcomes in patients who also had asthma was quite thrilling. That turns it into a really, really compelling indication. Plus, quite a few allergy-related indications exist that could work too. So we'll be sharing further updates on this down the road, within the next month.
Mary Tagliaferri
executiveRight. And we might also want to mention, when it comes to how type 1 diabetes treatments differ, that Pezil isn't a simple medication to administer. It's given as an IV infusion over a 14-day course for the up-dosing schedule; and, as you know, cytokine release syndrome is common in patients, so you do need to provide a sufficient number of other drugs — an antipyretic, an antihistamine, perhaps an antiemetic. And then clinicians must watch for lymphopenia, rash, and even elevated liver enzymes. So, by contrast, with ResTech's outpatient dosing regimen, where there's no routine monitoring and cytokine release syndrome doesn't occur, I think that also provides a highly differentiated and more favorable safety profile, plus a drug that's administered outside rather than as an IV infusion in an infusion center or even a hospital.
Samantha Semenkow
analystThanks so much.
Arthur He
analystHi there, Howard, and hello to everyone on the team. Great work on the progress you have made. Is my audio coming through clearly?
Arthur He
analystAll right, that works. So, I have a couple of things I would like to ask. I understand that in April you plan to share the extension data from the AA study. But if you are permitted to do so, could you let us know the number of patients who get through the extension phase? And once a patient reaches the end of the extension, are they able to decide to stay on the drug, or does everyone move into the off-treatment period? That covers my first question. My second question is whether you could provide a brief update regarding the LADY trial. Thank you.
Howard W. Robin
executiveJZ, would you like to handle the first question?
Jonathan Zalevsky
executiveOkay, very briefly. As we said back in December, 23 patients were still enrolled in the 16-week extension. Arthur, if you recall, we showed a waterfall plot, and those folks were the ones marked with green dots on it. So when the April data update arrives, that's when all of them will have finished the 52-week course of treatment. That covers those 23 individuals plus anybody who had already completed it before then. And in this study, treatment ends for every patient either at week 36 or week 52, depending on whether they entered the extension; after that point, each person gets followed for 24 weeks. Then, for the second question, Howard, I'll hand it over to you.
Howard W. Robin
executiveYes. I appreciate that, Arthur. Well, clearly, I’m not able to go into specifics regarding, you know, litigation of this kind. A trial had been set for last year. It was — this is in federal court. As a result of the government shutdown last year, the courts were closed, so it got pushed to this year. That trial is set for September 8, a jury trial in federal court in San Francisco. And we are completely dedicated to seeing this through. And we, you know, we definitely believe we suffered harm. And let’s watch how this unfolds in court. I hope that answers you as fully as I can right now. But thank you for asking.
Arthur He
analystGreat, thanks for taking my questions.
Andy Hsieh
analystThanks for taking our questions. Perhaps just one regarding a few of the macro developments over the last couple of weeks. Galderma, they sort of discussed growing confidence in the atopic dermatitis space; so I suppose part one, I'm curious whether that might change your market sizing guidance that was given during Morgan, and then also sort of a data update from Pfizer with its tri-specific asset in atopic dermatitis. Not a lot of numerical data, but, you know, sort of curious about your take on that. Thanks.
Howard W. Robin
executiveJZ, do you want to answer that one?
Jonathan Zalevsky
executiveOkay, so I'll begin with the Pfizer item, and after that, Mary, you can give the update on Galderma. To put it briefly — Pfizer shared a small amount of data in its press release, covering a few molecules among the multispecifics that inhibit either IL-4/13 and tislip, or 4/13 and IL-33. Their placebo-adjusted efficacy results looked quite encouraging. One point here — this raises a genuinely interesting question, since merging established mechanisms into multispecific agents, whether bi-specific or tri-specific, is one route to a combination-style strategy. Yet it also serves as a means of folding all the mechanisms we already know into a single agent. That could prove useful, though it is likewise an incremental path centered on agents that are known and validated. In our view, a mechanism such as Respag, which targets Tregs, offers a chance to give patients efficacy that is far more holistic and possibly more comprehensive. The reason is that what a Treg really seeks to accomplish is correcting the disease's underlying pathology — not removing pathways that drive disease as such, but repairing what made those pathways disease-driving to begin with. That explains why, in atopic dermatitis with continued dosing, we believe we have been seeing efficacy climb to such a degree, along with deep maintenance and the possibility that patients truly fare better. It's quite striking. I mean, with most medicines you take, things tend to get worse for you as time passes. Yet in the Respag studies, patients improve over time; so we see plenty of opportunity there. We're also quite enthusiastic that Respag sits much further along. Right? So considering the programs now entering phase 3, Respag holds a very competitive position, and it's a novel MOA. It also has the chance to deliver a highly differentiated opportunity for patients. Mary, I'll hand it to you for the Galderma question — summary.
Howard W. Robin
executiveMary, before you say anything, I want to build on something JZ mentioned. So, that's a really good question. I believe the scale of this market matters a lot. As I mentioned before, by the middle of the 2030s, it should reach $35 billion. And only roughly 10% of atopic dermatitis patients are on a biologic, so there's huge potential for this market to expand. There's plenty of space for different mechanisms of action. So I don't see that turning into a genuine obstacle. I do believe Jay Z is completely right that as an agonist — adopting a Treg agonist strategy — our approach is very, very distinct from, say, IL-13, IL-4, or any similar blockade. So we'll watch how things develop, but this market we're in is extremely, extremely big. And I believe there's space for quite a few different opportunities. Mary, would you like to go ahead?
Mary Tagliaferri
executiveRight, no. I'd simply put it this way: whenever we examine the Arcadia phase 3 results for — keep in mind those studies paired treatment with topical corticosteroids. And patients genuinely dislike slathering topical corticosteroids all over themselves. By the time someone begins a biologic, it's because they've already spent a very long period relying on topicals, which failed to bring their disease under control. If you review those phase 3 programs, EASI-75 falls somewhere between 42% and 44% for enolizumab when combined with the topical corticosteroid. I'd encourage everyone to revisit our February presentation; we displayed those placebo subjects — the placebo subjects from the induction phase who crossed over — across both 16 weeks of treatment and 24 weeks of treatment, and there EASI-75 exceeded what we observed with nimo plus topical corticosteroids. It reached 53% at week 16 and 58% at week 24. So I believe even, as I say, we observed quite rapid itch relief. And afterward, when you compare head-to-head at 75, those tags appear to deliver a deeper response than nalizumab plus a topical corticosteroid; so, from the standpoint Howard mentioned, naturally this is an enormous market, and plenty of room exists for multiple agents. I think when we set our data alongside nimo plus, we have extremely compelling data that would truly demonstrate a physician would prefer to choose an agent offering a deeper EASI-75 for their patients' benefit. So thank you for the question.
Howard W. Robin
executiveThank you so much. I'd also like to express my appreciation to all of you for being here today and for sticking with us. We truly appreciate that a great deal. And my thanks go out to our team members, who put in relentless effort for the sake of patients. Working side by side, we've turned our scientific idea into genuine and potentially significant treatment choices for those patients. Coming up, we're eager to kick off our phase 3 trials in atopic dermatitis this June, and to present our 52-week alopecia areata results in April. So keep watching. Thank you, everyone.
Operator
operatorThanks so much. That brings us to the end of today's conference call. We appreciate everyone for joining in. You're free to disconnect at this point. Wishing all of you a wonderful day.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Nektar Therapeutics transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Nektar Therapeutics earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Nektar Therapeutics or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.